Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reifenberger

Showing results (451-460 of 562) with videos related to

Pageof 57
Sort By:
Neurological Research and Practice|May 22, 2022
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomasLukas Bunse, Anne-Kathleen Rupp, Isabel Poschke, et al.
Cell Death & Disease|March 21, 2026
Berzosertib enhances the sensitivity of pediatric diffuse midline glioma H3K27-altered cells to radiotherapyNikita Gorainow, Felix Sander, Daniel Picard, et al.
Redox Biology|December 24, 2021
Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic TaoismChristina Wilms, Klaudia Lepka, Felix Häberlein, et al.
Acta Neuropathologica|January 6, 2024
Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytomaMichael Weller, Jörg Felsberg, Bettina Hentschel, et al.
Nature Communications|June 13, 2015
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modellingMarc Zuckermann, Volker Hovestadt, Christiane B Knobbe-Thomsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 9, 2020
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine PETElena K Bauer, Gabriele Stoffels, Tobias Blau, et al.
Neuro-Oncology|July 28, 2018
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatmentHendrik Witt, Dorothee Gramatzki, Bettina Hentschel, et al.
Clinical Neuropathology|March 31, 2023
Update on quality assurance in neuropathology: Summary of the round robin trials on <i>TERT</i> promoter mutation, <i>H3-3A</i> mutation, 1p/19q codeletion, and <i>KIAA1549::BRAF</i> fusion testing in Germany in 2020 and 2021Sandra Pohl, Lora Dimitrova, Maja Grassow-Narlik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survivalAurélie Ernst, Stefanie Hofmann, Rezvan Ahmadi, et al.
Neuro-Oncology|June 6, 2023
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guidelineFelix Sahm, Sebastian Brandner, Luca Bertero, et al.
Pageof 57

Showing results (451-460 of 562) with videos related to

Sort By:
Pageof 57
Neurological Research and Practice|May 22, 2022
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomasLukas Bunse, Anne-Kathleen Rupp, Isabel Poschke, et al.
Cell Death & Disease|March 21, 2026
Berzosertib enhances the sensitivity of pediatric diffuse midline glioma H3K27-altered cells to radiotherapyNikita Gorainow, Felix Sander, Daniel Picard, et al.
Redox Biology|December 24, 2021
Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic TaoismChristina Wilms, Klaudia Lepka, Felix Häberlein, et al.
Acta Neuropathologica|January 6, 2024
Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytomaMichael Weller, Jörg Felsberg, Bettina Hentschel, et al.
Nature Communications|June 13, 2015
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modellingMarc Zuckermann, Volker Hovestadt, Christiane B Knobbe-Thomsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 9, 2020
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine PETElena K Bauer, Gabriele Stoffels, Tobias Blau, et al.
Neuro-Oncology|July 28, 2018
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatmentHendrik Witt, Dorothee Gramatzki, Bettina Hentschel, et al.
Clinical Neuropathology|March 31, 2023
Update on quality assurance in neuropathology: Summary of the round robin trials on <i>TERT</i> promoter mutation, <i>H3-3A</i> mutation, 1p/19q codeletion, and <i>KIAA1549::BRAF</i> fusion testing in Germany in 2020 and 2021Sandra Pohl, Lora Dimitrova, Maja Grassow-Narlik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survivalAurélie Ernst, Stefanie Hofmann, Rezvan Ahmadi, et al.
Neuro-Oncology|June 6, 2023
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guidelineFelix Sahm, Sebastian Brandner, Luca Bertero, et al.
Pageof 57